Graftskin data show improved wound healing:
This article was originally published in Clinica
Organogenesis has moved closer to submission for US approval of its Graftskin human skin product after presenting analysis of trial data. Results from the prospective, randomised trial presented at the Symposium on Advanced Woundcare in San Diego this month, show that Graftskin was 60% more effective than standard compression in closing wounds completely in a median time of 57 days compared with 181 for compression. The company is completing analysis of secondary endpoints, including factors such as oedema, pain and exudate, in preparation for a submission for marketing approval.
You may also be interested in...
Health technology assessment body says that while iRhythm Technologies’ Zio XT service improves cardiac arrhythmia detection, more data must be collected to address evidence gaps about its benefit.
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.